VRTX vs. REGN, BMY, SNY, GSK, ZTS, PFE, TAK, ABT, RPRX, and BGNE
Should you be buying Vertex Pharmaceuticals stock or one of its competitors? The main competitors of Vertex Pharmaceuticals include Regeneron Pharmaceuticals (REGN), Bristol-Myers Squibb (BMY), Sanofi (SNY), GSK (GSK), Zoetis (ZTS), Pfizer (PFE), Takeda Pharmaceutical (TAK), Abbott Laboratories (ABT), Royalty Pharma (RPRX), and BeiGene (BGNE).
Regeneron Pharmaceuticals (NASDAQ:REGN) and Vertex Pharmaceuticals (NASDAQ:VRTX) are both large-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their analyst recommendations, institutional ownership, dividends, community ranking, risk, earnings, profitability, media sentiment and valuation.
In the previous week, Regeneron Pharmaceuticals had 5 more articles in the media than Vertex Pharmaceuticals. MarketBeat recorded 26 mentions for Regeneron Pharmaceuticals and 21 mentions for Vertex Pharmaceuticals. Regeneron Pharmaceuticals' average media sentiment score of 0.67 beat Vertex Pharmaceuticals' score of 0.66 indicating that Vertex Pharmaceuticals is being referred to more favorably in the news media.
Regeneron Pharmaceuticals has a beta of 0.11, indicating that its share price is 89% less volatile than the S&P 500. Comparatively, Vertex Pharmaceuticals has a beta of 0.35, indicating that its share price is 65% less volatile than the S&P 500.
Vertex Pharmaceuticals received 59 more outperform votes than Regeneron Pharmaceuticals when rated by MarketBeat users. Likewise, 75.65% of users gave Vertex Pharmaceuticals an outperform vote while only 66.58% of users gave Regeneron Pharmaceuticals an outperform vote.
Vertex Pharmaceuticals has a net margin of 36.68% compared to Vertex Pharmaceuticals' net margin of 30.14%. Regeneron Pharmaceuticals' return on equity of 21.91% beat Vertex Pharmaceuticals' return on equity.
Regeneron Pharmaceuticals presently has a consensus price target of $977.77, indicating a potential upside of 10.71%. Vertex Pharmaceuticals has a consensus price target of $429.45, indicating a potential upside of 8.04%. Given Vertex Pharmaceuticals' stronger consensus rating and higher possible upside, research analysts clearly believe Regeneron Pharmaceuticals is more favorable than Vertex Pharmaceuticals.
Regeneron Pharmaceuticals has higher revenue and earnings than Vertex Pharmaceuticals. Regeneron Pharmaceuticals is trading at a lower price-to-earnings ratio than Vertex Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
83.3% of Regeneron Pharmaceuticals shares are held by institutional investors. Comparatively, 91.0% of Vertex Pharmaceuticals shares are held by institutional investors. 8.8% of Regeneron Pharmaceuticals shares are held by insiders. Comparatively, 0.2% of Vertex Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.
Summary
Vertex Pharmaceuticals beats Regeneron Pharmaceuticals on 10 of the 18 factors compared between the two stocks.
Get Vertex Pharmaceuticals News Delivered to You Automatically
Sign up to receive the latest news and ratings for VRTX and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding VRTX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Vertex Pharmaceuticals Competitors List
Related Companies and Tools
